Screener
Amphastar Pharmaceuticals AMPH Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Revenue by Product | ||||||
| Baqsimi | $100K— | —— | —— | —— | —— | |
| Primatenemist | $0— | —— | —— | $0— | $0— | |
| Revenue by Geography | ||||||
| CN | $4.56M+1,425% | $2.48M+2,964% | $925K-57.8% | $1.88M+956% | $299K-80.9% | |
| FR | $7M-1.6% | $9.65M+22.8% | $10.63M+15.0% | $9.68M+114% | $7.11M+61.3% | |
| US | $172.34M+3.2% | $159.04M-2.2% | $171.55M-2.0% | $180.28M-3.3% | $167M-5.3% |
FAQ
- How does Amphastar Pharmaceuticals break its business down?
- Amphastar Pharmaceuticals (AMPH) reports revenue by product across 2 parts — Baqsimi and Primatenemist. Each is extracted from the segment footnotes and tracked over time.
- Where does Amphastar Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Amphastar Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
